Evidence map›Paper›PMID 40193172›Full record

ArticleJournal of cosmetic dermatology2025

In Vitro Lethal Effects of Benzyl Benzoate Concentrations of 25%, 10%, and 5% on Demodex folliculorum Mites: An Experimental Study With a Control Group.

İlkay Can, Murat Durdu

Abstract readComparative Study
In one paragraph

Article in Journal of cosmetic dermatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

İlkay CanDepartment of Dermatology, Faculty of Medicine, Balıkesir University, Balıkesir, Turkey.ORCID https://orcid.org/0000-0002-0115-0321
Murat DurduDepartment of Dermatology, Faculty of Medicine, Başkent University, Adana, Turkey.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDemodex mites have been implicated in the pathogenesis of many dermatologic diseases, especially rosacea. Although many case reports have been published about the treatment of skin diseases caused by Demodex folliculorum mite, no relevant treatment algorithm has been developed so far. In this context, we investigated the lethal effects of different doses of benzyl benzoate on this mite.

objectiveTo compare the lethal effects of 3 different doses of benzyl benzoate on Demodex folliculorum mites with those of a control group consisting of immersion oil. MATERIALS AND

methodsWaste samples collected from rosacea patients were included in the study. Four different groups of 20 mites were formed. Each group was exposed to 5%, 10%, and 25% concentrations of benzyl benzoate, respectively. Immersion oil was used as a negative control group. The movements of the mites were monitored with a digital microscope. The time to death of the mites was recorded.

resultsThe mean time to death of mites was 26 ± 2,9, 120 ± 7.6, and 168 ± 15 min after application of benzyl benzoate at concentrations of 25%, 10%, and 5%, respectively. The mean time to death of mites in immersion oil applied as a negative control group was 192 ± 6.4 min. Among the study groups, only the 25% benzyl benzoate group had a statistically significantly shorter mean time to death compared to the control group (p = 0.03).

conclusionWhile low concentrations of benzyl benzoate were ineffective in the treatment of demodicosis, benzyl benzoate at high concentrations, e.g., 25%, was found to be effective in its treatment.

Indexed as

BenzoatesMite InfestationsMitesAnimalsDose-Response Relationship, DrugHumansRosaceaBenzoatesbenzyl benzoatebenzyl benzoatedemodex folliculorumrosacea

Identifiers

PMID40193172
PMCPMC11975156

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.